 Predictive Oncology Inc. NASDAQ:POAI said it ended the second quarter of 2022 with a strong balance sheet, a solid cash position, commensurate equity, and no debt. The Minnesota-based company recognized net sales revenue of 400,000 for the three months ended June 30, 2022, an increase of 6 from the year-ago period, mainly due to a 100,000 sales contribution from its zPREDICTA subsidiary which is pioneering tumor-specific 3D cell culture services for anti-cancer drug testing. 